Stockscreener 앱 받기
7.39
1.47%
-0.11
Lexeo Therapeutics Inc 주식(LXEO)의 최신 뉴스
Aug Update: Is SLAB subject to activist investor interestWeekly Investment Recap & Real-Time Stock Entry Alerts - baoquankhu1.vn
Aug Decliners: Will Lexeo Therapeutics Inc outperform its industry peersEarnings Risk Report & Weekly Top Gainers Trade List - baoquankhu1.vn
Price Action: Will Lexeo Therapeutics Inc outperform its industry peersAnalyst Upgrade & Fast Moving Stock Watchlists - baoquankhu1.vn
LXEO: Cardiac gene therapy programs show strong efficacy, safety, and commercial readiness - TradingView — Track All Markets
Heart-disease gene therapy race heating up as Lexeo posts data - BioWorld MedTech
Lexeo Therapeutics stock falls 23% despite Cantor maintaining Overweight rating - Investing.com Canada
Lexeo Therapeutics (NASDAQ:LXEO) Trading Down 6.5%Should You Sell? - MarketBeat
Day Trade: Will Lexeo Therapeutics Inc stock outperform growth indexesJuly 2025 Setups & Safe Entry Point Alerts - Bộ Nội Vụ
H.C. Wainwright lowers Lexeo Therapeutics stock price target on PKP2 data concerns - Investing.com Canada
Oppenheimer reiterates Outperform rating on Lexeo Therapeutics stock By Investing.com - Investing.com Canada
Aug Intraday: Will Lexeo Therapeutics Inc. stock deliver shareholder valueJuly 2025 Price Swings & Stepwise Trade Signal Guides - Bộ Nội Vụ
Oppenheimer reiterates Outperform rating on Lexeo Therapeutics stock - Investing.com
Lexeo Therapeutics (NASDAQ:LXEO) Given "Buy" Rating at Chardan Capital - MarketBeat
Lexeo Therapeutics price target lowered to $10 from $13 at H.C. Wainwright - TipRanks
Lexeo’s gene therapy shows promising results for heart condition By Investing.com - Investing.com Nigeria
Lexeo Therapeutics Reflects Structural Trends In Clinical Biotech - Kalkine Media
Update Recap: Is Lexeo Therapeutics Inc forming a bullish divergenceDay Trade & Safe Capital Growth Plans - baoquankhu1.vn
Lexeo Therapeutics (NASDAQ:LXEO) Shares Gap DownHere's What Happened - MarketBeat
Gold Rises Sharply; Lyra Therapeutics Shares Plunge - Benzinga
Lexeo Therapeutics Reports Positive Interim HEROIC-PKP2 Trial Results - TipRanks
Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 - TradingView — Track All Markets
Lexeo Therapeutics stock falls after PKP2 gene therapy data By Investing.com - Investing.com Canada
Lexeo Therapeutics stock falls after PKP2 gene therapy data - Investing.com
Lexeo’s gene therapy shows promising results for heart condition - Investing.com
Lexeo Therapeutics Reports Positive Interim Results from HEROIC-PKP2 Trial of LX2020 for Arrhythmogenic Cardiomyopathy - Quiver Quantitative
Lexeo Therapeutics Announces Positive Interim Phase I/II - GlobeNewswire
Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Up 9% – Here’s Why - Defense World
Institutional investors have a lot riding on Lexeo Therapeutics, Inc. (NASDAQ:LXEO) with 56% ownership - simplywall.st
Why Lexeo Therapeutics Inc. stock is a must watch in 2025July 2025 EndofMonth & AI Forecast Swing Trade Picks - Улправда
Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO) and Xenon (XENE) - The Globe and Mail
Lexeo Therapeutics (NASDAQ:LXEO) Trading Up 9%Still a Buy? - MarketBeat
Why Lexeo Therapeutics Inc. stock remains a top recommendationJuly 2025 WrapUp & Safe Capital Preservation Plans - Улправда
Why Lexeo Therapeutics Inc. stock appeals to analystsWeekly Risk Report & Advanced Technical Analysis Signals - Улправда
Why Lexeo Therapeutics Inc. stock attracts global investors2025 Market Overview & Fast Entry High Yield Stock Tips - ulpravda.ru
Lexeo Therapeutics Announces Research Collaboration with Johnson & Johnson to Explore Targeted Cardiac Delivery of Aav Gene Therapy - marketscreener.com
Lexeo Therapeutics Announces Research Collaboration with Johnson & Johnson to Advance Cardiac Gene Therapy Using Impella Technology - Quiver Quantitative
Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy - GlobeNewswire
Wall Street rallies behind Lexeo Therapeutics (LXEO)’s gene therapy pipeline - MSN
Lexeo Therapeutics (NASDAQ:LXEO) Shares Down 5.5%What's Next? - MarketBeat
Contrasting Lexeo Therapeutics (NASDAQ:LXEO) and Wellgistics Health (NASDAQ:WGRX) - Defense World
Lexeo Therapeutics (NASDAQ:LXEO) Shares Down 3.5%Here's What Happened - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Wall Street Rallies Behind Lexeo Therapeutics (LXEO)’s Gene Therapy Pipeline - Insider Monkey
Lexeo Therapeutics CEO R. Nolan Townsend to Present at J.P. Morgan Healthcare Conference 2026 in San Francisco - Quiver Quantitative
Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Genetic medicine firm Lexeo joins speakers at major J.P. Morgan event - Stock Titan
Lexeo Therapeutics, Inc.(NasdaqGM:LXEO) added to S&P Biotechnology Select Industry Index - marketscreener.com
What dividend safety score for Lexeo Therapeutics Inc. stockGap Down & Low Drawdown Trading Strategies - Улправда
Why Lexeo Therapeutics Inc stock is a must watch in 2025Quarterly Risk Review & High Conviction Buy Zone Alerts - moha.gov.vn
Is Lexeo Therapeutics Inc. stock near bottom after declineTrade Risk Report & High Accuracy Investment Signals - Улправда
Lexeo Therapeutics Earnings Notes - Trefis
Will Lexeo Therapeutics Inc. stock deliver shareholder valuePortfolio Profit Report & High Accuracy Trade Alerts - Улправда
Dow Update: Can Lexeo Therapeutics Inc. stock resist sector downturnsJuly 2025 PostEarnings & High Win Rate Trade Tips - Улправда
Bearish Setup: Is Lexeo Therapeutics Inc. stock near bottom after declineMarket Weekly Review & Risk Controlled Swing Alerts - ulpravda.ru
Can Lexeo Therapeutics Inc. stock resist sector downturnsJuly 2025 News Drivers & Real-Time Stock Price Movement Reports - Улправда
Raymond James Initiates Coverage on Lexeo Therapeutics With Strong Buy Rating, $25 Price Target - marketscreener.com
This Valvoline Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Raymond James Initiates Coverage of Lexeo Therapeutics (LXEO) with Strong Buy Recommendation - Nasdaq
Raymond James initiates Lexeo Therapeutics stock with Strong Buy rating By Investing.com - Investing.com Canada
Biotech Momentum Carries After-Hours Trading Gains - RTTNews
Certain Pre-Funded Warrants of Lexeo Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-DEC-2025. - marketscreener.com
Certain Warrants of Lexeo Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-DEC-2025. - marketscreener.com
4.73%
0.92%
자본화:
|
볼륨(24시간):